Pharma Mar Sa · BME:PHM
Pharma Mar Sa — Investor Presentation (September 2026)
25 slides from Pharma Mar Sa's investor presentation, September 2026
Slide 1: Corporate Presentation
Corporate Presentation World leader in the development and commercialization of anticancer drugs of marine origin. September 2026
Slide 2: Our vision
CORPORATE PRESENTATION 2 Our vision We are inspired by the sea, driven by science, and motivated to improve the lives of cancer patients by delivering novel medicines. We intend to continue to be the world leader in marine medicinal discovery, development and innovation.
Slide 3: Corporate Overview
CORPORATE PRESENTATION 3 Corporate Overview Global Fully Integrated Commercial Stage Biotech. Developing marine-inspired oncology drugs Discovery Platform Strengthening Oncology Pipeline Diversified pipeline with late and early-stage assets 3 Approved Oncology Products Established European oncology
Slide 4: The Plan for Growth
CORPORATE PRESENTATION 4 The Plan for Growth Continue delivering value to shareholders Lurbinectedin Other drugs Corporate development Approved for 1L maintenance in PM54 in PoC Phase I/IIb Looking for in-licensing SCLC in both the US and EU products to market Phase 3 trial with lurbinectedin in PM5
Slide 5: PharmaMar Pipeline
CORPORATE PRESENTATION 5 PharmaMar Pipeline Expanding our Expertise in Oncology PHASE 1 PHASE 2 PHASE 3 MARKET YONDELIS (trabectedin) Soft tissue sarcoma Monotherapy 2nd/3rd line Ovarian cancer +PLD (pegylated 2nd/3rd line liposomal doxorubicin) APLIDIN (plitidepsin) R/R Multiple myeloma1 +dexametha
Slide 6: Practice changing in 1st Line maintenance in US and launched in the EU
Practice changing in 1st Line maintenance in US and launched in the EU
Slide 7: Small Cell Lung Cancer (SCLC): A still high unmet medical need
CORPORATE PRESENTATION 7 Small Cell Lung Cancer (SCLC) A still high unmet medical need Among all Lung Cancers Limited treatment options Low survival rate in both the US and Europe at 5 years ~15% SCLC ~ 62,000 ~ 30,000 20222 20223 Highly aggressive tumour Newly diagnosed patients each year 5-year su
Slide 8: Zepzelca (lurbinectedin) Extensive Stage SCLC Treatment Paradigm
CORPORATE PRESENTATION 8 Zepzelca (lurbinectedin) Extensive Stage SCLC Treatment Paradigm Strong positioning opportunity FIRST LINE SUBSEQUENT INDUCTION MAINTENANCE THERAPY Platinum/Etoposide Atezolizumab + +Lurbinectedin Atezolizumab - Lurbinectedin FDA or Durvalumab - Topotecan (sensitive) Approve
Slide 9: Lurbinectedin: 1st line maintenance positioning
CORPORATE PRESENTATION 9 Lurbinectedin: 1st line maintenance positioning Phase 3 trial (IMforte) for first line-maintenance SCLC INDUCTION PHASE MAINTENANCE PHASE Atezolizumab 1,200 mg q3wk + lurbinectedin 3.2 mg/m2 q3wk • Atezolizumab + CO-PRIMARY Extensive-stage carboplatin + RANDOMIZATION • IRC-a
Slide 10: Positive results from the IMforte Phase 3 clinical trial 1/4
CORPORATE PRESENTATION 10 Positive results from the IMforte Phase 3 clinical trial 1/4 Statistically significant and clinically meaningful OS & PFS benefit IRF-PFS from randomization into maintenance phase Lurbi + Atezo Atezo IRF-PFS (n=242) (n=241) Events, n(%) 174 (71.9) 202 (83.8) PFS, median (95
Slide 11: Positive results from the IMforte Phase 3 clinical trial 2/4
CORPORATE PRESENTATION 11 Positive results from the IMforte Phase 3 clinical trial 2/4 Statistically significant and clinically meaningful OS & PFS benefit OS from randomization into maintenance phase OS assessment started from randomization into the maintenance phase (median time from induction to
Slide 12: Positive results from the IMforte Phase 3 clinical trial 3/4
CORPORATE PRESENTATION 12 Positive results from the IMforte Phase 3 clinical trial 3/4 Safety summary during the maintenance phase Lurbi + Atezo Atezo Lurbi + Atezo Atezo Patients with ≥1 AE, n (%) Patients with ≥1 AE, n (%) (n=242) (n=240) (n=242) (n=240) All-cause AEs 235 (97.1) 194 (80.8) Lurbine
Slide 13: Positive results from the IMforte Phase 3 clinical trial 4/4
CORPORATE PRESENTATION 13 Positive results from the IMforte Phase 3 clinical trial 4/4 All-cause AEs with incidence ≥10% in either arm Lurbi + Atezo Atezo “This approach is truly practice changing and has been readily adopted in clinical Any AE 97.1% 80.8% practice.” Nausea 36.4% 4.2% Dr. Joshua K.
Slide 14: Lurbinectedin. Pathway to market in EU
CORPORATE PRESENTATION 14 Lurbinectedin. Pathway to market in EU Key events 2024 2025 2026 2027 2028 IMforte trial (Q1) End of (H1) Regulatory (H1) EU marketing Market access Lurbinectedin + atezolizumab recruitment submission authorization in other EMA european 1st line maintenance (Q4) Positive (H
Slide 15: Lurbinectedin – European incidence
CORPORATE PRESENTATION 15 Lurbinectedin – European incidence SCLC in EU Total lung cancer incidence in Europe 484,306 patients (1) SCLC 13%-15% 62,960 patients Population Lung Cancer SCLC Country / Area 2022 (Million) Incidence 2022 incidence (3) Germany 83.8 62,025 8,063 Italy 60.3 43,808 5,695 Fra
Slide 16: Leiomyosarcoma
| LEIOMYOSARCOMA ws ae —
Slide 17: Leiomyosarcoma: Incidence and treatment paradigm
CORPORATE PRESENTATION 17 Leiomyosarcoma Incidence and treatment paradigm INCIDENCE ~2,100(1) in USA FIRST LINE SECOND LINE - Doxorubicin - Trabectedin FDA Approved - Ifosfamide - Pazopanib - Doxorubicin + - Dacarbazine NCCN trabectedin - Ifosfamide Guidelines - Gemcitabine based regimen INCIDENCE ~
Slide 18: Zepzelca (lurbinectedin)-Leiomyosarcoma
CORPORATE PRESENTATION 18 Zepzelca (lurbinectedin)-Leiomyosarcoma Phase III Recruitment ended in May 2026 PATIENTS INCLUDED Doxorubicin* 50 mg/m2 + • Metastatic Lurbinectedin 2.2 mg/m2 • Uterine/STS LMS + G-CSF D1 q3wk • No prior chemo • ECOG 0-1 Primary endpoint: Doxorubicin* 25 mg/m2 + PFS by IRC
Slide 19: Lurbinectedin. Total Addressable Market
CORPORATE PRESENTATION 19 Lurbinectedin. Total Addressable Market European Union European Union PharmaMar Territories Western EU Commercial agreements UK, Scandinavia and Eastern Europe: Inmedica Pharma Greece, Cyprus and Balkans: Genesis Pharma Rest of the world Partner Territories US and rest of t
Slide 20: Clinical development: Pathway to growth
2 CORPORATE PRESENTATION 3 0 Clinical development Pathway to growth PM54 2025 2026 2027 2028 / 2029 • Potential 2nd generation of Lurbinectedin • Novel active transcription inhibitor Phase I Phase II Phase III • Early signs of activity in solid tumors • Good safety profile • Synergy in combination w
Slide 21: PM54. Development pathways
CORPORATE PRESENTATION 3 21 PM54. Development pathways Expanding indications and combination strategies to maximize its potential COMBINATION 1 2 INDICATIONS 3 FUTURE GROWTH STRATEGIES Monotherapy Monotherapy ✓ Monotherapy ✓ Melanoma Expansion into major indications In combination: ✓ In combination:
Slide 22: Financials
CORPORATE PRESENTATION 22 Financials Profitable, solid and stable financial position Robust cash position M€ Total revenues by product 2024 M€ 250 200 174.9M€ 120.0M€ Total revenues Zepzelca 28.5M€ EU Distribution 150 by product 56.2M€ Royalties 69% Zepzelca 6.7M€ API 231.8 216.5 212.6 100 157.0 31%
Slide 23: Key Events
CORPORATE PRESENTATION 23 Key Events Catalyst Calendar • Out-license (Japan) DONE • Approval lurbinectedin in 1L maintenance in US DONE • Approval lurbinectedin in 1L maintenance in EU DONE • Full recruitment SaLuDo trial DONE • Lurbinectedin: commercial launch in Germany and Austria DONE • Potentia
Slide 24: Disclaimer
CORPORATE PRESENTATION 24 Disclaimer This presentation contains forward-looking statements that This presentation is made pursuant to Section 5(d) of the U.S. include information about possible or assumed future results of Securities Act of 1933, as amended, and is intended solely for the business,
Slide 25: www.pharmamar.com
7 www.pharmamar.com